Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Studying the differential efficacy of postsymptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model.

Torgeman A, Schwartz A, Diamant E, Baruchi T, Dor E, Ben David A, Pass A, Barnea A, Tal A, Rosner A, Rosen O, Zichel R.

Dis Model Mech. 2018 Sep 27;11(9). pii: dmm035089. doi: 10.1242/dmm.035089.

2.

A Novel Rabbit Spirometry Model of Type E Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.

Diamant E, Pass A, Rosen O, Ben David A, Torgeman A, Barnea A, Tal A, Rosner A, Zichel R.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02379-17. doi: 10.1128/AAC.02379-17. Print 2018 Apr.

3.

An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins.

Torgeman A, Diamant E, Levin L, David AB, Epstein E, Girshengorn M, Mazor O, Rosenfeld R, Zichel R.

Vaccine. 2017 Dec 19;35(52):7213-7216. doi: 10.1016/j.vaccine.2017.11.015. Epub 2017 Nov 22.

PMID:
29174678
4.

Efficacy of inactivation of viral contaminants in hyperimmune horse plasma against botulinum toxin by low pH alone and combined with pepsin digestion.

Torgeman A, Mador N, Dorozko M, Lifshitz A, Eschar N, White MD, Wolf DG, Epstein E.

Biologicals. 2017 Jul;48:24-27. doi: 10.1016/j.biologicals.2017.06.003. Epub 2017 Jun 17.

PMID:
28633975
5.

Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations.

Torgeman A, Ozeri E, Ben David A, Diamant E, Rosen O, Schwartz A, Barnea A, Makovitzki A, Mimran A, Zichel R.

Toxins (Basel). 2017 May 29;9(6). pii: E180. doi: 10.3390/toxins9060180.

6.

Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs.

Diamant E, Torgeman A, Ozeri E, Zichel R.

Toxins (Basel). 2015 May 29;7(6):1854-81. doi: 10.3390/toxins7061854. Review.

7.

Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate.

Ben David A, Torgeman A, Barnea A, Zichel R.

Protein Expr Purif. 2015 Jun;110:122-9. doi: 10.1016/j.pep.2015.02.008. Epub 2015 Feb 26.

PMID:
25727047
8.

The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Ben David A, Diamant E, Barnea A, Rosen O, Torgeman A, Zichel R.

Clin Vaccine Immunol. 2013 Aug;20(8):1266-73. doi: 10.1128/CVI.00268-13. Epub 2013 Jun 12.

9.

Role of protein kinase C and the Sp1-p53 complex in activation of p21(WAF-1) expression by 12-O-tetradecanoylphorbol-13-acetate in human T cells.

Schavinsky-Khrapunsky Y, Huleihel M, Aboud M, Torgeman A.

Oncogene. 2003 Aug 14;22(34):5315-24.

PMID:
12917633
10.

TPA activates p21WAF-1 promoter in human T-cells through its second most upstream Sp1 site.

Schavinsky-Khrapunsky Y, Huleihel M, Aboud M, Torgeman A.

Biochem Biophys Res Commun. 2003 May 16;304(4):696-700.

PMID:
12727210
11.

Activation of HTLV-I long terminal repeat by apoptosis inducing agents: mechanism and implications for HTLV-I pathogenicity (review).

Schavinsky-Khrapunsky Y, Gold E, Ben-Aroya Z, Torgeman A, Aboud M, Huleihel M.

Int J Mol Med. 2003 Jan;11(1):3-11. Review.

PMID:
12469209
12.

Activation of HTLV-I long terminal repeat by stress-inducing agents and protection of HTLV-I-infected T-cells from apoptosis by the viral tax protein.

Torgeman A, Ben-Aroya Z, Grunspan A, Zelin E, Butovsky E, Hallak M, Löchelt M, Flügel RM, Livneh E, Wolfson M, Kedar I, Aboud M.

Exp Cell Res. 2001 Nov 15;271(1):169-79.

PMID:
11697893
13.

Sp1-p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C.

Torgeman A, Mor-Vaknin N, Zelin E, Ben-Aroya Z, Löchelt M, Flügel RM, Aboud M.

Virology. 2001 Mar 1;281(1):10-20.

Supplemental Content

Loading ...
Support Center